看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
, m i# J3 l$ m J; g! Q' Y6 s
. N5 `# U0 Z$ U4 l7 S6 p0 m4 `* l/ n
Currently available feasibility data for possible combination strategies.
. R( p, z7 O! B& S————————————————————————————————
! b5 K& Y# U2 BCombination Feasibility according to preliminary data - r- U' P- S/ Y. U+ V
——————————————————————————————————
& g; L/ {" J3 ]: ^8 B7 PBevacizumab + sorafenib Yes, reduced dose ( m' {! q& J+ y7 Z' j
Bevacizumab + sunitinib† No ( \/ W' u$ A4 L2 k5 Z) ]
Bevacizumab + temsirolimus Yes / W; e3 M- |1 C. r6 E; J
Bevacizumab + everolimus Yes
9 y2 B3 k! w. B2 K7 e# O8 JSorafenib + sunitinib ?
! s. ]0 J+ q; {+ WSorafenib + temsirolimus Yes, reduced dose 1 a7 t6 f! B* i0 F/ B
Sorafenib + everolimus Yes, reduced dose 5 A/ w9 V* T& R& v2 W* v
Sunitinib + temsirolimus† No 3 ]& |3 M* g" d, f+ x; @7 P
Sunitinib + everolimus ?
, [! `) L6 y5 a: E: O: nTemsirolimus + everolimus ? , J& B D. M# ]# L8 V6 }. A
————————————————————
* V9 v* m) {$ r; x! J% _9 \†Led to US FDA warning.
% V: t' l( ^0 O4 _# z" r?: As yet unattempted combination.
# V# L: X' M% E; ?9 a |